Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Mechanical Support & Haemodynamics with Dr Frederick Welt
Author(s): Frederick Welt Added: 6 months ago
Learn about haemodynamic guidance in cardiogenic shock, including early intervention, device selection, and exit strategies, from Dr Frederick Welt (University of Utah, US)This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr… View more

Intervention

MI/ACS
HFA 24: MONITOR-HF Subgroup Analysis
Author(s): Jasper J Brugts Added: 1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,… View more

Heart Failure
Aortic Pseudoaneurysm Rupture into the Right Ventricle
Author(s): Neel N Patel , Andrew O Zurick III Added: 1 month ago

Imaging & Diagnostics

Vascular Disease and Surgery
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
TTE and TEE in the New TAVR Era with Dr Victoria Delgado
Author(s): Victoria Delgado Added: 8 months ago
Navigate the evolving landscape of TAVI beyond conventional applications with Dr Victoria Delgado.This presentation, part of the Structural Interventions track, explores specialized applications including TAVI in small aortic annulus, examining insights from the SMART and RHEIA trials that demonstrate superior hemodynamics of transcatheter approaches, particularly in women who present with… View more

Demographic

Intervention
Research Area(s) / Expertise: Job title: Director
Dr Dan Burkhoff is currently the Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation, New York, US.Dr Burkhoff's interest include cardiovascular modeling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices.He is also author of Harvi, an… View more
Thomas Weber
Job title: Associate Professor
Dr Thomas Weber is an Austrian cardiologist. He is Deputy Director of the Cardiology Department at the Klinikum Wels-Grieskirchen, in Wels, Austria.His clinical interests cover interventional cardiology, heart failure and hypertension while his scientific interests are pulsatile hemodynamics, arterial stiffness, vascular aging, 24-hour hemodynamics, heart failure, coronary artery disease,… View more
Cardiogenic Shock in Restrictive Cardiomyopathies
Author(s): Ossama K Abou Hassan , Ebere Chukwu , John Schmittner , et al Added: 8 months ago

Heart Failure
Research Area(s) / Expertise: Job title: Head of Hemodynamics and Interventional Cardiology
Prof Jose M de la Torreis an interventional cardiologist and Head of the Hemodynamics and Interventional Department of the Marques de Valdecilla University of Santander, ES. Prof Jose M de la Torre is member of the scientific committee of the Spanish Society of Cardiology and is fellow of the European Society of Cardiology. Former associate director of the Trans Catheter Therapeutics Meeting… View more
Aficamten Superior to Metoprolol in oHCM: MAPLE-HCM
Added: 4 weeks ago Source:  CFR Journal Radcliffe Cardiology
A prespecified, secondary analysis of the MAPLE-HCM trial has shown that aficamten monotherapy provides superior and rapid benefits across multiple domains of disease burden compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).¹ Aficamten is a next-in-class cardiac myosin inhibitor (CMI) designed to reduce myocardial hypercontractility by decreasing… View more

Heart Failure